Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Skin Diseases, Papulosquamous 1Skin Diseases 1Sarcoma, Synovial 1Sarcoma 1Psoriasis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plaque, Amyloid 1Myelodysplastic Syndromes 1Lymphoma, Follicular 1Lymphoma 1Liposarcoma, Myxoid 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Graft vs Host Disease 1Chondrosarcoma 1Bronchiolitis Obliterans Syndrome 1Arthritis, Rheumatoid 1Adenoma, Liver Cell 1

Interventions

baricitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Skin Diseases, Papulosquamous × baricitinib × Clear all
NCT01490632 2019-09-27

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

Eli Lilly and Company

Phase 2 Completed
271 enrolled 32 charts
Lymphoid

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous, Plaque, Amyloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡